Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

253.13 -0.84 (-0.33%)
Streaming Delayed Price Updated: 11:06 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
TechMediaBreaks – SS Innovations International, Inc. (NASDAQ: SSII) Surpasses Intuitive Surgical (NASDAQ: ISRG), Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT) for Top Surgical Robotics Award
Via Investor Brand Network
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
From Johnson & Johnson
Via Business Wire
News headline image
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
From BioMedWire
Via GlobeNewswire
News headline image
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
From Johnson & Johnson
Via Business Wire
News headline image
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
From Johnson & Johnson
Via Business Wire
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value
From AINewsWire
Via GlobeNewswire
News headline image
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
From Johnson & Johnson
Via Business Wire
News headline image
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
From Johnson & Johnson
Via Business Wire
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.